Tata 1mg turns EBITDA-positive across core units; to scale stores from 280 to 500+ in 12 months
Tata 1mg hit EBITDA breakeven across ePharmacy, diagnostics and D2C in Q4 FY26. Diagnostics crossed Rs 600 cr ARR (+40% YoY) across 19 NABL labs in 70 cities; D2C surpassed Rs 200 cr ARR with Specialty Pharma up 65%. Retail footprint to nearly double to 500+ stores within 12 months.
Tata 1mg turned EBITDA positive across core businesses in Q4 FY26. ePharmacy hit breakeven, diagnostics crossed Rs 600 cr ARR with 40% growth, D2C surpassed Rs 200 cr ARR. Plans to scale retail footprint from 280 to 500+ stores within 12 months.
Why this matters
Builds on Tata 1mg's FY26 EBITDA-positive milestone and Rs 600 cr diagnostics ARR, now layering an aggressive retail expansion to nearly 2x its store count alongside profitable core units.
Retail-company signals steady at 1,415 over 90 days, with health-retail scale-ups gaining share.